Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Jeffrey Weinberg

Director of Clinical Research - Dermatology
ST LUKE'S-ROOSEVELT HOSPITAL CENTER
Member of the Healthcare Council

Jeffrey Weinberg, MD, is the Director of the Clinical Research Center in the Department of Dermatology at St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center in New York. He is also an Assistant Clinical Professor in the Dermatology Department at Columbia University College of Physicians & Surgeons. Dr. Weinberg is involved in several clinical trials and is an Associate Editor of the journal Cutis, where he focuses on cutaneous infectious disease, eczema, and new treatments for psoriasis. Dr. Weinberg consults for Amgen and Genetech among others. (This is me - Update Profile)


Employment History
1999 - present Assistant Clinical Professor
Columbia University
1999 - present Director of Clinical Research - Dermatology
ST LUKE'S-ROOSEVELT HOSPITAL CENTER

GLG NewsSM Analyses by Jeffrey Weinberg(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Issues with Ustekinumab | 06-23-2008
Author: Jeffrey Weinberg, Director of Clinical Research - Dermatology, ST LUKE'S-ROOSEVELT HOSPITAL CENTER

On Tuesday, the FDA's Dermatologic and Ophthalmic Drug Advisory Panel voted unanimously to approve the use of the injectable drug for the treatment of plaque psoriasis, a severe skin disease. As the FDA usually follows the recommendations of its advisory panels when reviewing new drugs for approval,...

Ustekinumab | 12-19-2007
Author: Jeffrey Weinberg, Director of Clinical Research - Dermatology, ST LUKE'S-ROOSEVELT HOSPITAL CENTER

This drug is four times yearly This will be attractive to MDs and patients It is highly efficaciuous

GLG InstituteSM Seminars with Jeffrey Weinberg(?)

 

Recent Seminars

Request a project with Jeffrey Weinberg









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics